Stock Traders Buy High Volume of Novo Nordisk A/S Put Options (NYSE:NVO)

Novo Nordisk A/S (NYSE:NVO) was the target of unusually large options trading activity on Thursday. Stock investors acquired 58,638 put options on the company. This represents an increase of approximately 58% compared to the typical volume of 37,048 put options.

Analyst Ratings Changes

Several brokerages recently weighed in on NVO. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Finally, StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $140.20.

Novo Nordisk A/S Stock Up 0.4 %

NYSE NVO opened at $83.26 on Friday. Novo Nordisk A/S has a one year low of $80.05 and a one year high of $148.15. The company has a market cap of $373.61 billion, a P/E ratio of 26.94, a P/E/G ratio of 0.92 and a beta of 0.45. The business has a fifty day moving average price of $98.82 and a 200 day moving average price of $117.93. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94.

Hedge Funds Weigh In On Novo Nordisk A/S

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Raymond James & Associates increased its stake in shares of Novo Nordisk A/S by 1.0% in the 3rd quarter. Raymond James & Associates now owns 3,526,821 shares of the company’s stock worth $419,939,000 after acquiring an additional 36,223 shares during the last quarter. Natixis Advisors LLC grew its holdings in shares of Novo Nordisk A/S by 2.7% in the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after purchasing an additional 80,070 shares during the period. International Assets Investment Management LLC increased its position in Novo Nordisk A/S by 10,608.4% during the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock worth $215,942,000 after purchasing an additional 1,796,635 shares during the last quarter. DSM Capital Partners LLC raised its stake in Novo Nordisk A/S by 257,816.0% during the second quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock worth $227,516,000 after purchasing an additional 1,593,303 shares during the period. Finally, LPL Financial LLC boosted its holdings in Novo Nordisk A/S by 3.6% in the 3rd quarter. LPL Financial LLC now owns 1,362,782 shares of the company’s stock valued at $162,266,000 after purchasing an additional 47,496 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.